Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.

Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.

From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research.